Zak Mir speaks with Kunwar Shailubhai, CEO of Tiziana Life Sciences, are the markets, prospective investor understanding the business model?. As is often the case the focus is on a company delivering results. Given the multiple treatments Tiziana is well on the way to developing, the waiting game should be close to its conclusion.
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.
In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world.
This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
Article on Clinical Activity of OKT3
Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform
Third party research conducted by leading U.S. institutions to be published in a peer reviewed journal Crohn’s & Colitis 360 shows orally administered anti-CD3 resulted in anti-inflammatory gene expression with no serious treatment related adverse events up to a dose of 1 mg of OKT3
Tiziana’s platform oral monoclonal antibody (mAb) technology applicable to mAb’s on the market today which are currently available only through IV, addressing an enourmous market potential.
Tiziana’s Foralumab is the first fully human anti-CD3 mAb which has not shown anti-drug antibody (immune reaction) in humans
New York/London, 24 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, notes the advance publication of a scientific article by third party researchers in the peer reviewed journal Crohn’s & Colitis 360* titled, “Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis”(1) The published study was conducted at some of the leading medical research institutions in the world, including Harvard Medical School, Massachusetts General Hospital, and the Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital. These independent findings suggest potential clinical activity and support the safety of monoclonal antibodies (mAb’s) when administered orally.
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned